메뉴 건너뛰기




Volumn 26, Issue 8, 2010, Pages 1799-1807

Back pain during different sequential treatment regimens of teriparatide: Results from EUROFORS

Author keywords

Back pain; Postmenopausal osteoporosis; Raloxifene; Teriparatide; Vertebral fracture

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D;

EID: 77954750748     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.488516     Document Type: Article
Times cited : (36)

References (37)
  • 1
    • 28844464600 scopus 로고    scopus 로고
    • Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis
    • Silverman SL, Piziak VK, Chen P, et al. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005;32:2405-9
    • (2005) J Rheumatol , vol.32 , pp. 2405-9
    • Silverman, S.L.1    Piziak, V.K.2    Chen, P.3
  • 2
    • 0032524460 scopus 로고    scopus 로고
    • The association of radiographically detected vertebral fractures with back pain and function: A prospective study
    • Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
    • (1998) Ann Intern Med , vol.128 , pp. 793-800
    • Nevitt, M.C.1    Ettinger, B.2    Black, D.M.3
  • 3
    • 0036787976 scopus 로고    scopus 로고
    • Diagnostic evaluation of low back pain with emphasis on imaging
    • Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med 2002;137:586-97
    • (2002) Ann Intern Med , vol.137 , pp. 586-97
    • Jarvik, J.G.1    Deyo, R.A.2
  • 4
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
    • (2001) N Engl J Med , vol.344 , pp. 1434-41
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 5
    • 36148958951 scopus 로고    scopus 로고
    • Teriparatide compared with alendronate for the treatment of glucocorticoid-induced osteoporosis
    • Saag KG, Shane E, Boonen S, et al. Teriparatide compared with alendronate for the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
    • (2007) N Engl J Med , vol.357 , pp. 2028-39
    • Saag, K.G.1    Shane, E.2    Boonen, S.3
  • 6
    • 6344278780 scopus 로고    scopus 로고
    • Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
    • Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30
    • (2004) Arch Intern Med , vol.164 , pp. 2024-30
    • Lindsay, R.1    Scheele, W.H.2    Neer, R.3
  • 7
    • 24144443783 scopus 로고    scopus 로고
    • Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
    • Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-13
    • (2005) J Bone Miner Res , vol.20 , pp. 1507-13
    • Prince, R.1    Sipos, A.2    Hossain, A.3
  • 8
    • 30144439980 scopus 로고    scopus 로고
    • Reduced risk of back pain following teriparatide treatment: A meta-analysis
    • Nevitt MC, Chen P, Dore RK, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:273-80
    • (2006) Osteoporos Int , vol.17 , pp. 273-80
    • Nevitt, M.C.1    Chen, P.2    Dore, R.K.3
  • 9
    • 33749177248 scopus 로고    scopus 로고
    • Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: A meta-analysis
    • Nevitt MC, Chen P, Kiel DP, et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:1630-7
    • (2006) Osteoporos Int , vol.17 , pp. 1630-7
    • Nevitt, M.C.1    Chen, P.2    Kiel, D.P.3
  • 10
    • 65549090933 scopus 로고    scopus 로고
    • Sequential treatment of severe post-menopausal osteoporosis following teriparatide: Final results of the randomized, controlled European study of Forsteo (EUROFORS)
    • Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe post-menopausal osteoporosis following teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS). J Bone Miner Res 2009;24:726-36
    • (2009) J Bone Miner Res , vol.24 , pp. 726-36
    • Eastell, R.1    Nickelsen, T.2    Marin, F.3
  • 11
    • 52949131857 scopus 로고    scopus 로고
    • For the EUROFORS Investigators. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
    • Obermayer-Pietsch B, Marin F, McCloskey EV, et al. for the EUROFORS Investigators. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008;23:1591-600
    • (2008) J Bone Miner Res , vol.23 , pp. 1591-600
    • Obermayer-Pietsch, B.1    Marin, F.2    McCloskey, E.V.3
  • 12
    • 40849124001 scopus 로고    scopus 로고
    • For the EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
    • Boonen S, Marin F, Obermayer-Pietsch B, et al. for the EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-60
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 852-60
    • Boonen, S.1    Marin, F.2    Obermayer-Pietsch, B.3
  • 13
    • 57749170286 scopus 로고    scopus 로고
    • Bone density after teriparatide in patients with or without prior antiresorptive treatment: One-year results from the EUROFORS study
    • Minne H, Audran M, Simoes ME, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008;24:3117-28
    • (2008) Curr Med Res Opin , vol.24 , pp. 3117-28
    • Minne, H.1    Audran, M.2    Simoes, M.E.3
  • 14
    • 0020574134 scopus 로고
    • Studies with different types of visual analog scales for measurement of pain
    • Sriwatanakul K, Kelvie W, Lasagna L, et al. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983; 34:234-9
    • (1983) Clin Pharmacol Ther , vol.34 , pp. 234-9
    • Sriwatanakul, K.1    Kelvie, W.2    Lasagna, L.3
  • 15
    • 23744447531 scopus 로고    scopus 로고
    • Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass
    • McClung MR, San Martin J, Miller PD, et al. Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
    • (2005) Arch Intern Med , vol.165 , pp. 1762-8
    • McClung, M.R.1    San Martin, J.2    Miller, P.D.3
  • 16
    • 0037214255 scopus 로고    scopus 로고
    • The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
    • Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
    • (2003) J Bone Miner Res , vol.18 , pp. 9-17
    • Orwoll, E.S.1    Scheele, W.H.2    Paul, S.3
  • 17
    • 18644374464 scopus 로고    scopus 로고
    • A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    • Body J-J, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4528-35
    • Body, J.-J.1    Gaich, G.A.2    Scheele, W.H.3
  • 18
    • 33144473937 scopus 로고    scopus 로고
    • Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy
    • Ste-Marie LG, Schwartz SL, Hossain A, et al. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2006;21:283-91
    • (2006) J Bone Miner Res , vol.21 , pp. 283-91
    • Ste-Marie, L.G.1    Schwartz, S.L.2    Hossain, A.3
  • 19
    • 22744454945 scopus 로고    scopus 로고
    • The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis
    • Genant HK, Halse J, Briney WG, et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005;21:1027-34
    • (2005) Curr Med Res Opin , vol.21 , pp. 1027-34
    • Genant, H.K.1    Halse, J.2    Briney, W.G.3
  • 20
    • 0032869396 scopus 로고    scopus 로고
    • Time since vertebral fracture: An important variable concerning quality of life in patients with postmenopausal osteoporosis
    • Begerow B, Pfeifer M, Pospeschill M, et al. Time since vertebral fracture: an important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 1999;10:26-33
    • (1999) Osteoporos Int , vol.10 , pp. 26-33
    • Begerow, B.1    Pfeifer, M.2    Pospeschill, M.3
  • 21
    • 72449146207 scopus 로고    scopus 로고
    • Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)
    • Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93
    • (2009) Calcif Tissue Int , vol.85 , pp. 484-93
    • Langdahl, B.L.1    Rajzbaum, G.2    Jakob, F.3
  • 22
    • 0036828498 scopus 로고    scopus 로고
    • Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone[1-34]
    • Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone[1-34]. J Bone Miner Res 2002;17:2038-47
    • (2002) J Bone Miner Res , vol.17 , pp. 2038-47
    • Nakajima, A.1    Shimoji, N.2    Shiomi, K.3
  • 23
    • 0037022377 scopus 로고    scopus 로고
    • Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception
    • Dobolyi A, Ueda H, Uchida H, et al. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci USA 2002;99:1651-6
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 1651-6
    • Dobolyi, A.1    Ueda, H.2    Uchida, H.3
  • 24
    • 0034627883 scopus 로고    scopus 로고
    • Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmen-opausal women with existing vertebral fractures
    • Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmen-opausal women with existing vertebral fractures. Arch Intern Med 2000; 160:77-85
    • (2000) Arch Intern Med , vol.160 , pp. 77-85
    • Nevitt, M.C.1    Thompson, D.E.2    Black, D.M.3
  • 25
    • 6344232104 scopus 로고    scopus 로고
    • Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption and chronic back pain in postmenopausal women with osteoporosis
    • Iwamoto J, Takeda T, Sato Y, et al. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 2004; 23:383-9
    • (2004) Clin Rheumatol , vol.23 , pp. 383-9
    • Iwamoto, J.1    Takeda, T.2    Sato, Y.3
  • 26
    • 23444432918 scopus 로고    scopus 로고
    • Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendro-nate
    • Miller PD, Shergy WJ, Body J-J, et al. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendro-nate. J Rheumatol 2005;32:1556-62
    • (2005) J Rheumatol , vol.32 , pp. 1556-62
    • Miller, P.D.1    Shergy, W.J.2    Body, J.-J.3
  • 27
    • 33749184934 scopus 로고    scopus 로고
    • Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: A randomized double-blind controlled study
    • Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006;17:1659-65
    • (2006) Osteoporos Int , vol.17 , pp. 1659-65
    • Armingeat, T.1    Brondino, R.2    Pham, T.3
  • 28
    • 0033034387 scopus 로고    scopus 로고
    • Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures
    • Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999;18:266-7
    • (1999) Clin Rheumatol , vol.18 , pp. 266-7
    • Gangji, V.1    Appelboom, T.2
  • 29
    • 25844438772 scopus 로고    scopus 로고
    • Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: A systematic review of randomized, controlled trials
    • Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281-90
    • (2005) Osteoporos Int , vol.16 , pp. 1281-90
    • Knopp, J.A.1    Diner, B.M.2    Blitz, M.3
  • 30
    • 0036852676 scopus 로고    scopus 로고
    • The analgesic role of calcitonin following osteoporotic fracture
    • Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002;13:858-67
    • (2002) Osteoporos Int , vol.13 , pp. 858-67
    • Silverman, S.L.1    Azria, M.2
  • 31
    • 0036238699 scopus 로고    scopus 로고
    • Analgesic effects of calcitonin
    • Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone 2002;30(Suppl. 5): 71S-74S
    • (2002) Bone , vol.30 , Issue.SUPPL. 5
    • Lyritis, G.P.1    Trovas, G.2
  • 32
    • 33644638223 scopus 로고    scopus 로고
    • The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis
    • Papadokostakis G, Damilakis J, Mantzouranis E, et al. The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. Eur Spine J 2006;15:356-62
    • (2006) Eur Spine J , vol.15 , pp. 356-62
    • Papadokostakis, G.1    Damilakis, J.2    Mantzouranis, E.3
  • 33
    • 0030753267 scopus 로고    scopus 로고
    • Mechanisms and management of bone pain
    • Payne R. Mechanisms and management of bone pain. Cancer 1997; 80(Suppl. 8):1608-13
    • (1997) Cancer , vol.80 , Issue.SUPPL. 8 , pp. 1608-13
    • Payne, R.1
  • 34
    • 39549083894 scopus 로고    scopus 로고
    • Effects of strontium ranelate on spinal osteoarthritis progression
    • Bruyère O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-39
    • (2008) Ann Rheum Dis , vol.67 , pp. 335-39
    • Bruyère, O.1    Delferriere, D.2    Roux, C.3
  • 35
    • 33845993994 scopus 로고    scopus 로고
    • Skeletal pain in postmenopausal women with osteoporosis: Prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration
    • Scharla S, Oertel H, Helsberg K, et al. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin 2006;22:2392-402
    • (2006) Curr Med Res Opin , vol.22 , pp. 2392-402
    • Scharla, S.1    Oertel, H.2    Helsberg, K.3
  • 36
    • 44649126133 scopus 로고    scopus 로고
    • Efficacy of raloxifen in treatment of fibromyalgia in menopausal women
    • Sadreddini S, Molaeefard M, Noshad H, et al. Efficacy of raloxifen in treatment of fibromyalgia in menopausal women. Eur J Intern Med 2008; 19:350-5
    • (2008) Eur J Intern Med , vol.19 , pp. 350-5
    • Sadreddini, S.1    Molaeefard, M.2    Noshad, H.3
  • 37
    • 29144482953 scopus 로고    scopus 로고
    • Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?
    • Papadokstakis G, Katonis P, Damilakis J, et al. Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis? Eur Spine J 2005;14:977-81
    • (2005) Eur Spine J , vol.14 , pp. 977-81
    • Papadokstakis, G.1    Katonis, P.2    Damilakis, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.